James A. Reeves
About
James A. Reeves is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, James A. Reeves has authored 59 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 20 papers in Molecular Biology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James A. Reeves's work include Cancer Treatment and Pharmacology (14 papers), Cancer Genomics and Diagnostics (11 papers) and Multiple Myeloma Research and Treatments (9 papers). James A. Reeves is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Cancer Genomics and Diagnostics (11 papers) and Multiple Myeloma Research and Treatments (9 papers). James A. Reeves collaborates with scholars based in United States, United Kingdom and Canada. James A. Reeves's co-authors include Christian Manegold, Rafael Rosell, David H. Johnson, Judith Ochs, Steven D. Averbuch, Ronald B. Natale, John Grous, Vincent A. Miller, Giorgio V. Scagliotti and Giuseppe Giaccone and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
James A. Reeves
57 papers receiving 2.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| James A. Reeves United States | 17 | 1.7k | 1.4k | 926 | 536 | 351 | 59 | 2.6k | ||
| Leslie B. Lee United States | 13 | 790 0.5× | 988 0.7× | 1.0k 1.1× | 391 0.7× | 325 0.9× | 13 | 2.3k | ||
| Celine Wilke United States | 8 | 960 0.6× | 905 0.6× | 777 0.8× | 407 0.8× | 639 1.8× | 20 | 2.2k | ||
| Shuchi S. Pandya United States | 19 | 980 0.6× | 900 0.6× | 895 1.0× | 304 0.6× | 365 1.0× | 69 | 2.1k | ||
| Wael A. Harb United States | 23 | 1.4k 0.8× | 759 0.5× | 923 1.0× | 265 0.5× | 423 1.2× | 118 | 2.5k | ||
| Christian Scheffold United States | 25 | 1.0k 0.6× | 1.0k 0.7× | 900 1.0× | 346 0.6× | 431 1.2× | 75 | 2.3k | ||
| Jason McCoy United States | 14 | 882 0.5× | 634 0.5× | 649 0.7× | 681 1.3× | 219 0.6× | 30 | 1.8k | ||
| Yusri Elsayed United States | 22 | 1.1k 0.7× | 606 0.4× | 1.1k 1.1× | 414 0.8× | 208 0.6× | 51 | 2.4k | ||
| Vincent Haddad United Kingdom | 16 | 1.5k 0.9× | 1.3k 1.0× | 907 1.0× | 284 0.5× | 485 1.4× | 36 | 2.9k | ||
| M. Naveed Shaik United States | 19 | 834 0.5× | 523 0.4× | 1.1k 1.1× | 573 1.1× | 134 0.4× | 42 | 2.1k | ||
| Éric Legouffe France | 24 | 1.3k 0.8× | 848 0.6× | 1.3k 1.4× | 1.1k 2.0× | 518 1.5× | 49 | 3.2k |
Countries citing papers authored by James A. Reeves
Since
Specialization
Citations
This map shows the geographic impact of James A. Reeves's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James A. Reeves with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James A. Reeves more than expected).
Fields of papers citing papers by James A. Reeves
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by James A. Reeves. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James A. Reeves. The network helps show where James A. Reeves may publish in the future.
Co-authorship network of co-authors of James A. Reeves
This figure shows the co-authorship network connecting the top 25 collaborators of James A. Reeves. A scholar is included among the top collaborators of James A. Reeves based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James A. Reeves. James A. Reeves is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bessudo, Alberto, Abdul Haseeb, James A. Reeves, et al.. (2024). Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer. Clinical Colorectal Cancer. 23(3). 285–294.
2.
Falchook, Gerald S., James A. Reeves, Sunil Gandhi, et al.. (2024). A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer. Cancer Immunology Immunotherapy. 73(4). 72–72.
3.
Hart, Lowell L., et al.. (2024). Abstract 2565: Vitamin D deficiency and outcomes in prostate cancer patients: A real-world database. Cancer Research. 84(6_Supplement). 2565–2565.
4.
McKean, Meredith, Bartosz Chmielowski, Marcus O. Butler, et al.. (2023). 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Annals of Oncology. 34. S651–S651.
5.
Lim, Emerson A., James A. Reeves, David R. Spigel, et al.. (2022). 1396P Phase II study of AZD4635 in combination with durvalumab or oleclumab in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. 33. S1182–S1183.
6.
Spring, Laura M., Hyo S. Han, Minetta C. Liu, et al.. (2022). Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nature Cancer. 3(8). 927–931.
7.
McFarlane, Joshua J., Mark D. Kochenderfer, Mark R. Olsen, et al.. (2020). Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. Clinical Genitourinary Cancer. 18(6). 469–476.e4.
8.
N., Kim, Celestia S. Higano, Brent A. Blumenstein, et al.. (2017). Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. The Lancet Oncology. 18(4). 473–485.
9.
Hainsworth, John D., James A. Reeves, Joseph R. Mace, et al.. (2016). A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). Targeted Oncology. 11(5). 643–653.
10.
Yardley, Denise A., James A. Reeves, Elizabeth Claire Dees, et al.. (2016). Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clinical Breast Cancer. 16(6). 471–479.e1.
11.
N., Kim, Celestia S. Higano, Brent A. Blumenstein, et al.. (2015). Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.. Journal of Clinical Oncology. 33(15_suppl). 5009–5009.
12.
Hainsworth, John D., F. Anthony Greco, Eric Raefsky, et al.. (2014). Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 14(4). 277–283.
13.
Hainsworth, John D., et al.. (2013). High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clinical Genitourinary Cancer. 11(3). 283–289.e1.
14.
Borson, R., Graydon Harker, James A. Reeves, et al.. (2012). Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer. 12(5). 322–330.
15.
Motzer, Robert J., Thomas E. Hutson, James A. Reeves, et al.. (2012). Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz Trial. Annals of Oncology. 23. ixe13–ixe13.
16.
Meluch, Anthony A., Dianna Shipley, David Waterhouse, et al.. (2011). High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma (RCC): A Sarah Cannon Research Institute phase II trial.. Journal of Clinical Oncology. 29(15_suppl). e15101–e15101.
17.
MacVicar, Gary R., Filippo Greco, James A. Reeves, et al.. (2008). 209 POSTER An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer. European Journal of Cancer Supplements. 6(12). 66–66.
18.
Dosoretz, Daniel E., James H. Rubenstein, Michael J. Katin, et al.. (1998). Small-Cell Lung Carcinoma. American Journal of Clinical Oncology. 21(4). 333–337.
19.
Rubenstein, James H., Daniel E. Dosoretz, Michael J. Katin, et al.. (1995). Low doses of prophylactic cranial irradiation effective in limited stage small cell carcinoma of the lung. International Journal of Radiation Oncology*Biology*Physics. 33(2). 329–337.
20.
Zuckerman, Kenneth S., AF LoBuglio, & James A. Reeves. (1990). Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high-dose doxorubicin-containing regimen.. Journal of Clinical Oncology. 8(2). 248–256.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Leslie B. Lee Breakdown of academic impact, for papers by Celine Wilke Breakdown of academic impact, for papers by Shuchi S. Pandya Breakdown of academic impact, for papers by Wael A. Harb Breakdown of academic impact, for papers by Christian Scheffold Breakdown of academic impact, for papers by Jason McCoy Breakdown of academic impact, for papers by Yusri Elsayed Breakdown of academic impact, for papers by Vincent Haddad Breakdown of academic impact, for papers by M. Naveed Shaik Breakdown of academic impact, for papers by Éric Legouffe